Therapeutic advances and application of PARP inhibitors in breast cancer
Targeting of DNA repair pathway is the main therapeutic approach for BRCA1 and BRCA2 associated tumors, including breast cancer. BRCA1/2 genes play a pivotal role in HRR pathway. Mutations in BRCA1/2 leads to DDR deficiency, which cause the increasing of genome instability, thus rendering cancer cel...
Saved in:
| Main Authors: | Teng Zhou, Jian Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S193652332500141X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PARP inhibitors are a new area in the treatment of breast cancer
by: V. P. Letyagin
Published: (2014-08-01) -
Bioinformatics-based identification of key genes for Olaparib resistance in breast cancer: prognostic implications and therapeutic relevance
by: Kezhen Shen, et al.
Published: (2025-06-01) -
The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments – parallels with other neurodegenerative disorders
by: Dahlia A. Ordaz, et al.
Published: (2025-06-01) -
Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants
by: Michele Milella, et al.
Published: (2025-02-01) -
Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant <i>BRCA1</i>-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge
by: Chi-Ting Shih, et al.
Published: (2024-11-01)